Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease (Q28266116)

Behavioural assessment of mice lacking D1A dopamine receptors

Europe PubMed Central

title

Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease (English)

0 references

1 reference

0 references

Jack J Chen

1

0 references

David M Swope

series ordinal

2

0 references

Khashayar Dashtipour

series ordinal

3

0 references

Kelly E Lyons

series ordinal

4

0 references

language of work or name

English

0 references

publication date

December 2009

0 references

published in

Pharmacotherapy

0 references

volume

29

0 references

issue

12

0 references

page(s)

1452-67

0 references

cites work

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

20 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease

20 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

A controlled trial of rotigotine monotherapy in early Parkinson's disease

20 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Clinical practice. Diagnosis and initial management of Parkinson's disease

20 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Early intervention in Parkinson's disease: epidemiologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Duodenal levodopa infusion for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Dopamine stimulation via infusion in the lateral ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Transcutaneous delivery of levodopa: enhancement by fatty acid synthesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Drug delivery systems. 6. Transdermal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Transdermal administration of bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

In vivo iontophoretic administration of ropinirole hydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

21 January 2018

Transdermal Rotigotine

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Rotigotine transdermal system for perioperative administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Impulse control disorders and pathological gambling in patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Translating safety, efficacy and compliance into economic value for controlled release dosage forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.29.12.1452